Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO321 in Advanced Refractory Solid Tumors
NCT07748117Phase 1Not yet recruiting
- Sponsor
- GeneSail Biotech
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GO321 in solid tumor, sponsored by GeneSail Biotech. Primary endpoints: Adverse Events at 6 months, Serious Adverse Events at 6 months and 2 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
GO321
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07748117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07748117.